MediPharm Labs Corp.
LABS.TO
TSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 9.07% | -18.77% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 9.07% | -18.77% | |||
| Cost of Revenue | -3.76% | -21.93% | |||
| Gross Profit | 30.99% | -12.75% | |||
| SG&A Expenses | 0.00% | -1.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -5,435.71% | -100.55% | |||
| Total Operating Expenses | -2.62% | -17.02% | |||
| Operating Income | 108.07% | -3.06% | |||
| Income Before Tax | 100.45% | 55.83% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 100.45% | 55.83% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 100.45% | 55.83% | |||
| EBIT | 108.07% | -3.06% | |||
| EBITDA | 172.21% | -7.36% | |||
| EPS Basic | 100.00% | 54.55% | |||
| Normalized Basic EPS | 111.11% | 10.00% | |||
| EPS Diluted | 100.00% | 54.55% | |||
| Normalized Diluted EPS | 111.11% | 10.00% | |||
| Average Basic Shares Outstanding | 0.16% | 0.75% | |||
| Average Diluted Shares Outstanding | 0.16% | 0.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||